^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFRvIII expression

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Phase 2
Masonic Cancer Center, University of Minnesota
Withdrawn
Last update posted :
11/24/2023
Initiation :
06/28/2024
Primary completion :
12/31/2024
Completion :
06/30/2025
EGFR
|
EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression
|
dordaviprone (ONC201)
Phase 1
University of Pennsylvania
Completed
Last update posted :
06/22/2023
Initiation :
03/11/2019
Primary completion :
02/27/2021
Completion :
02/27/2021
EGFR • MGMT • TERT
|
EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation
|
Keytruda (pembrolizumab) • LXF821
Phase 1/2
Northwell Health
Completed
Last update posted :
02/10/2016
Initiation :
03/01/2006
Primary completion :
05/01/2014
Completion :
05/01/2014
PTEN
|
EGFR overexpression • PTEN expression • EGFRvIII expression • PTEN overexpression • EGFRVIII overexpression
|
erlotinib
Phase 1
John Sampson
Completed
Last update posted :
01/21/2016
Initiation :
03/01/2007
Primary completion :
02/01/2013
Completion :
02/01/2013
IL2RA • CD4 • IL7R • ISG20
|
EGFRvIII expression
|
temozolomide • Rintega (rindopepimut) • Simulect (basiliximab) • Zinbryta (daclizumab)